Skip to search formSkip to main contentSkip to account menu

GS-9256

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Cyclic PeptidesPhosphinic Acids

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Preclinical Characterization of the Novel HCV NS3 Protease Inhibitor GS-9256
Background GS-9256 is an inhibitor of HCV NS3 protease with a macrocyclic structure and novel phosphinic acid pharmacophore… 
2017
2017
Antiviral response and resistance analysis of treatment‐naïve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS‐9256
2014
2014
Current race in the development of DAAs (direct-acting antivirals) against HCV.
2014
2014
Genome-Wide Association Study to Characterize Serum Bilirubin Elevations in Patients with HCV Treated with Gs-9256, An HCV Ns3 Serine Protease Inhibitor
Background Protease inhibitors for the treatment of HCV can cause mild and reversible elevations of unconjugated bilirubin. We… 
2014
2014
Binding kinetics, potency, and selectivity of the hepatitis C virus NS3 protease inhibitors GS-9256 and vedroprevir.
2012
2012
Pharmacokinetic / Pharmacodynamic Predictors of Clinical Potency for 1 Hepatitis C Non-Nucleoside Polymerase and Protease Inhibitors 2 3
1 Hepatitis C Non-Nucleoside Polymerase and Protease Inhibitors 2 3 Authors: Micaela B. Reddy, Peter N. Morcos, Sophie Le Pogam… 
2011
2011
425 FOUR-WEEK TREATMENT WITH GS-9256 AND TEGOBUVIR (GS-9190), ± RBV ± PEG, RESULTS IN ENHANCED VIRAL SUPPRESSION ON FOLLOW-UP PEG/RBV THERAPY, IN GENOTYPI 1A/1B HCV PATIENTS
2011
2011
1232 IN VITRO STUDIES ON THE POTENTIAL FOR THE HEPATITIS C VIRUS PROTEASE INHIBITORS GS-9256 AND GS-9451 TO AFFECT BILIRUBIN ELIMINATION
2011
2011
779 PRECLINICAL CHARACTERIZATION OF THE NOVEL HCV NS3 PROTEASE INHIBITOR GS-9256
2010
2010
[Inhibitors of hepatitis C virus--therapeutic possibilities].
The search for new drugs against HCV contains new ways to obtain pro-drugs which inhibit translation and block viral proteins… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)